坦洛新治疗前列腺增生的效果及安全性探讨(2)
第1页 |
参见附件。
[2] Okada H,Kamidono S,Yoshioka T,et a1.Α compara-tive study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients[J].BJU International,2000,85(6):676.
[3] Lee E.Clinical comparison of selective and non—selec—tive ala-adrenoreceptor antagonists in benign prostatic hyperplasia:studies on tamsu/osin in a fixed dose and te—razosin inincreasing doses[J].Br J Urol,1997,80(7):606.
[4] de Mey C,Michel,Mc Ewen J,et al.Α double—blind comparison ofterazosin and tamsutosin on their differen—tial effects on ambulatory blood pressure and nocturnal orthostatic stress testing[J].Eur Urol,1 998,33(8):481.
[5] 钟惟德,蔡岳斌,胡建波,等.α1受体阻滞剂治疗前列腺增生症的疗效-成本分析[J].广东药学院学报,2010,1l(21):138-139.
[6] Souverein PC,Herings RM,De la Rosette JJ,et a1.Evaluating adverse cardiovascular effects of drug treat—ment for benign prostatic hyperplasia(BPH):Methodo—logical considerations[J].J Clin Epidemiol,2001,54(5):518.
[7] Clifford GM,Richard DT.Drug or symptom-induced depression in men treated with alphal--blockers for be--nign prostatic hyperplasia?Α nested case-control study[J].Pharmacoepidemiol Drug Saf,2002,23(11):55.
[8] 金兰.两种选择性α受体阻断剂在治疗前列腺增生症中的疗效比较[J].江苏药学与临床研究,2009,27(11):131-132.
[9] 熊鹰,叶璐,任宇,等.特拉唑嗪、非那雄胺和坦索罗辛治疗良性前列腺增生症的有效性评价[J].中国循征医学杂志,2010,25(16):448-449.
[10] 宋健.邵强.杜林栋,等.前列隙增生患者逼尿肌肾上腺素α1Α/α1D受体的表达及其作用[J].临床泌尿杂志,2008,23(6):472-474.
[11] 翟竣渡.盐酸坦洛新在良性前列腺增生手术中的应用[J].中国基层医药,2010,17(10):1408-1409.
[12] 李连印, 姜君仪, 刘俊江,等. 非那雄胺对前列腺增生患者骨密度影响的随机双盲研究[J]. 山东医药,2011,51(8):95-96.
(收稿日期:2014-07-03)
您现在查看是摘要介绍页,详见PDF附件。